CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04172987
NCT04172987Phase 1Completed
CompareCT.gov

Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

Eli Lilly and Company·interventional·Posted Nov 21, 2019·Updated Mar 27, 2023

In Brief

A Phase 1 clinical trial evaluating Tirzepatide and EE/NGM for Healthy. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected. Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 21, 2019
Enrollment StartFeb 26, 2020
Primary CompletionFeb 9, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.6 years ago

Interventions

Tirzepatidedrug

Administered SC

EE/NGMdrug

Combination oral contraceptive administered orally